Amniox Medical
26 articles about Amniox Medical
-
TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain
3/8/2021
Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a dosing study using its Investigational New Drug (IND) TTAX03 to treat facet joint pain resulting from Osteoarthritis (OA).
-
Recently Published Study Publication Suggests CLARIX FLO Amniotic Membrane/Umbilical Cord Particulate Provides Benefits in Moderate to Severe Knee Osteoarthritis
11/9/2020
74% of patients treated with CLARIX® FLO demonstrated clinically significant improvement at 12 months, signifying its potential in delaying Total Knee Arthroplasty (TKA)
-
Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft to Treat Complex Wagner Grade 3-4 Diabetic Foot Ulcers
6/30/2020
Company's first biologic license application candidate TTAX01 to enter Investigational New Drug Phase 3 Trials for Diabetic Foot Ulcer indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs
-
One-year Follow-up Study Results Find Cryopreserved Umbilical Cord Allograft for Treatment of Wagner Grade 3-4 Diabetic Foot Ulcers to be Safe with Higher than Expected Rates of Healing
6/1/2020
Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from the one-year follow-up study to their Phase 2 open label, multicenter pilot study of Cryopreserved Umbilical Cord allograft TTAX01.
-
Latest Complex Wound Care Research from Amniox Highlighted at SAWC Fall 2019 Meeting
10/28/2019
Scientific Posters Showcase Successful Treatment of Complex Wounds using NEOX® Cryopreserved Umbilical Cord Allograft to Accelerate Healing and Restore Function
-
TissueTech Appoints Dr. Frank Young Executive Vice President of Regulatory Affairs
5/10/2018
TissueTech Inc., pioneers of the development and clinical application of amniotic tissue-based products, announced today the appointment of Dr. Frank Young as Executive Vice President of Regulatory Affairs.
-
AMNIOX Medical Awarded Premier Agreement for Regenerative Medicine Products
12/11/2017
Dec. 11, 2017 15:19 UTC AMNIOX Medical Awarded Premier Agreement for Regenerative Medicine Products Offers Access to Amniotic Membrane Products to Premier Members ATLANTA--( BUSINESS WIRE )-- AMNIOX Medical, Inc., a TissueTech, Inc. company, has been awarded a group purchasing agreement for Regenerative Skin Grafting Products with Premier. Effective January 1, 2018, the new agreement allows Premier members, at the
-
AMNIOX Medical Introduces RESPINA at NASS 2017
10/26/2017
AMNIOX Medical, Inc., a TissueTech, Inc. company, highlighted the introduction of RESPINA its cryopreserved umbilical cord/amniotic membrane matrix at the North American Spine Society’s (NASS) annual meeting in Orlando, FL, October 25 - 27.
-
Amniox Medical Release: Study Demonstrating Improved Outcomes In Pain Reduction And Function For Discectomy Patients With CLARIX 100 Highlighted In Medical Journal
7/10/2017
-
Amniox Medical Enters Into Agreement With Intalere
6/8/2017
-
New Clinical Evidence Continues To Support The Effectiveness And Value Of Amniox Medical Products
5/8/2017
-
Amniox Medical Obtains Federal Supply Schedule Contract For NEOX And CLARIX Product Lines
4/17/2017
-
Amniox Medical Highlights Three Studies Demonstrating Effectiveness Of Umbilical Cord Tissue For Treating Chronic Wounds
4/7/2017
-
Amniox Medical Highlights Study Demonstrating Improved Outcomes In Patients Treated With CLARIX Regenerative Matrix As An Adjunct To Lumbar Discectomy
10/26/2016
-
Amniox Medical Highlights Studies Finding CLARIX FLO And CLARIX CORD 1K Improving Foot And Ankle Outcomes
7/25/2016
-
New Evidence Highlights Effectiveness And Value Of Amniox Medical Products
4/14/2016
-
Amniox Medical’s NEOX CORD 1K Is The First Cryopreserved Umbilical Cord Allograft That Can Be Safely Refrigerated For Two Years
4/14/2016
-
Amniox Medicals NEOX CORD 1K Is The First Cryopreserved Umbilical Cord Allograft That Can Be Safely Refrigerated For Two Years
4/14/2016
-
Palmetto Medicare Now Covering Amniox Medical Products
4/13/2016
-
WPS Now Covering Amniox Medical Products
3/31/2016